Recordati

Recordati is a global pharmaceutical company founded in 1926 in Correggio, Italy, and listed on the Italian stock exchange. It develops and commercialises medicines across three segments: specialty and primary care treatments for common and chronic diseases, consumer healthcare products, and rare disease therapeutics. The group employs over 4,450 people and serves approximately 150 countries.

The company's rare disease work, pursued on a dedicated basis since 2007, covers little-known conditions including Cushing's disease, acromegaly and rare cancers, with activity spanning endocrinology and oncology. Its broader portfolio continues a long-standing focus on chronic conditions, alongside a consumer healthcare range. Operating across roughly 150 markets places the group within the heavily regulated and highly cross-border framework that governs pharmaceutical development, approval and commercialisation.

Recordati traces its origins to a small family-run pharmacy established by Giovanni Recordati and marks 100 years of operation in 2026. The company states a patient-centric mission, holding that access to health is a right rather than a privilege and that every rare disease patient deserves the best available treatment option.